11 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 16 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 11, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Filariasis: new trials by email Literature Review of Filariasis trials Research Report on Filariasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Better Options for Lymphatic Filariasis Treatment MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies | Phase 3 | Recruiting | Medicines Development for Global Health | 5100 | 2026-09-28 | 2026-10-07 |
| 21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia Albendazole 400mg, Placebo - Loiasis With Positive Blood Microfilaremia, Loiasis | Phase 3 | Not yet recruiting | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 100 | 2025-01-15 | 2024-09-26 |
| A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects Levamisole 3 days, Levamisole 5 days, Placebo - Loiasis | Phase 2 / Phase 3 | Unknown | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 99 | 2024-06-21 | 2024-09-20 |
| Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis Moxidectin, Ivermectin - Onchocerciasis | Phase 3 | Active not recruiting | Medicines Development for Global Health | 323 | 2021-05-03 | 2025-12-23 |
| Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole Moxidectin, Ivermectin, Albendazole - Onchocerciasis | Phase 3 | Completed | Medicines Development for Global Health | 12979 | 2021-05-03 | 2026-03-03 |
| Adjunctive Ivermectin Mass Drug Administration for Malaria Control Ivermectin, Placebo, Dihydroartemisinin-piperaquine - Malaria,Falciparum, Neglected Tropical Diseases | Phase 3 | Unknown | London School of Hygiene and Tropical Medicine | 24000 | 2021-05-03 | 2022-02-24 |
| Moxidectin for LF, Cote d'Ivoire (DOLF) Ivermectin, Diethylcarbamazine, Albendazole - Lymphatic Filariasis | Phase 3 | Completed | Washington University School of Medicine | 164 | 2020-08-20 | 2026-01-29 |
| A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis | Phase 3 | Completed | The Task Force for Global Health | 235 | 2019-01-15 | 2021-06-24 |
| Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1 - Trachoma, Yaws | Phase 3 | Completed | Lihir Medical Centre | 20000 | 2018-10-01 | 2019-02-28 |
| A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis | Phase 3 | Completed | The Task Force for Global Health | 220 | 2018-06-19 | 2021-06-24 |
| A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis | Phase 3 | Completed | The Task Force for Global Health | 219 | 2018-02-16 | 2021-03-17 |
| Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Albendazole - Helminthiasis, Filariasis | Phase 3 | Completed | University of Washington | 357716 | 2017-10-04 | 2026-01-22 |
| Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Ivermectin, Albendazole - Malaria, Lymphatic Filariasis | Phase 2 / Phase 3 | Completed | Colorado State University | 2712 | 2015-06-01 | 2019-01-04 |
| Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana IVM plus ALB, IVM - Onchocerciasis | Phase 3 | Completed | University Hospitals Cleveland Medical Center | 375 | 2014-06-01 | 2019-04-26 |
| IVM Alone vs ALB + IVM Against Onchocerciasis Ivermectin, Albendazole - Onchocerciasis | Phase 3 | Completed | University Hospitals Cleveland Medical Center | 272 | 2012-04-01 | 2017-08-29 |
| Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Moxidectin, Ivermectin - Onchocerciasis | Phase 3 | Completed | Medicines Development for Global Health | 1497 | 2009-04-01 | 2018-01-31 |
Elephantiasis, Filarial (8) · Onchocerciasis (7) · Lymphedema (3) · Scabies (3) · Strongyloidiasis (3) · Loiasis (2) · Malaria (2) · Neglected Diseases (2) · Ancylostomiasis (1) · Helminthiasis (1) · Malaria, Falciparum (1) · Onchocerciasis, Ocular (1) · Trachoma (1) · Yaws (1)
Infections (16) · Nematode Infections (16) · Parasitic Diseases (16) · Secernentea Infections (16) · Spirurida Infections (16) · Helminthiasis (15) · Skin Diseases (10) · Skin Diseases, Infectious (10) · Skin Diseases, Parasitic (10) · Skin and Connective Tissue Diseases (10) · Vector Borne Diseases (9) · Hemic and Lymphatic Diseases (8) · Lymphatic Diseases (8) · Mosquito-Borne Diseases (8)
Albendazole (8) · Ivermectin (8) · moxidectin (4) · Doxycycline (3) · Diethylcarbamazine (2) · Albumins (1) · Azithromycin (1) · Intravital Microscopy (1) · Levamisole (1)
Medicines Development for Global Health (4) · The Task Force for Global Health (3) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (2) · University Hospitals Cleveland Medical Center (2) · Colorado State University (1) · Lihir Medical Centre (1) · London School of Hygiene and Tropical Medicine (1) · University of Washington (1) · Washington University School of Medicine (1)
Democratic Republic of the Congo (3) · Ghana (3) · Côte d’Ivoire (2) · India (2) · Benin (1) · Burkina Faso (1) · Fiji (1) · Guinea-Bissau (1) · Liberia (1) · Malawi (1) · Mali (1) · Papua New Guinea (1) · Republic of the Congo (1) · Sri Lanka (1) · United States (1)
Eric Ottesen, MD (3) · Benjamin Koudou, PhD (2) · Tony Ukety, MD, DO, MPH (2) · Anna R Last, MBChB PhD (1) · Brian D. Foy, PhD (1) · Catherine Bjerum, MD, MPH (1) · Christopher L King, MD, PhD (1) · James W Kazura, MD (1) · Judd L Walson, MD, MPH (1) · Lucy John, MD (1) · Nicholas O Opoku, MBChB, MSc (1) · Philip Budge, MD, PhD (1) · Roch K Dabire, PhD (1)
PMID 11873261, PMID 22610930, PMID 32228663, PMID 10656038, PMID 29346377, PMID 29361335, PMID 30878222, PMID 33137100, PMID 33930024, PMID 33979325, PMID 34226233, PMID 34281614, PMID 34403424, PMID 35476631, PMID 35701056, PMID 35803632, PMID 36461087, PMID 36897877, PMID 36917597, PMID 37036890, PMID 37419638, PMID 37616301, PMID 37721964, PMID 37899143, PMID 38175837, PMID 38319937, PMID 39242171, PMID 39380086, PMID 39551062, PMID 40345209, PMID 40615414, PMID 40752908, PMID 42264499, PMID 42684913, PMID 42848323
R01AI155739 (1)